R&D News | pharmaphorum

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

A look back at 2023: Smith + Nephew

This year brought about a whole gambit of news and developments, of conferences and launches, all coming in thick and fast and excited about the pharmaceutical industry an

News

AI specialist Fauna grabs $494m Lilly obesity alliance

A US biotech that is trying to find new avenues for treating human diseases by studying the genomics of animal species, Fauna Bio, has agreed a deal with Eli Lilly focusin

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Cytokinetics rockets on positive heart drug trial

BMS strikes again, with $4.1bn RayzeBio takeover bid

AZ makes another cell therapy play with $1.2bn Gracell buy

A look back at 2023: Smith + Nephew

AI specialist Fauna grabs $494m Lilly obesity alliance

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks